Dr Terry Wahls Deserves More Respect youtube.com/shorts/Dd3WD...
43-year-old woman with headache and left inferior quadrantanopsia and right superior quadrantanopsia. MRI shows THIS! Diagnosis?
43 year old woman with dizziness, hiccups, nausea. MRI shows THIS lesion in the medulla! anti AQP4 neuromyelitis optica? No! Hint: her father has progressive gait decline and motor/sensory neuropathy. Diagnosis?
Medication for Multiple Sclerosis Fatigue Explained by Neurologist youtu.be/nWONMHdCQvo?...
For the true nerds: 48-year-old right-handed man with MS with right visual field loss with alexia without agraphia. He improved but had mild reading difficulty journals.sagepub.com/doi/epdf/10....
Potential multiple sclerosis treatments targeting Epstein-Barr virus. One of the authors is a colleague of mine, Dr. Hannah Zhao-Fleming www.frontiersin.org/journals/imm...
If you take a b-cell depleting drug (ocrevus, rituximab kesimpta) for multiple sclerosis while breastfeeding, will your infant's b-cell be affected? In this study (n=10), only one infant had b-cell counts below the 5th percentile. pubmed.ncbi.nlm.nih.gov/42226810/
Dr. John Corboy on the risk of relapse/new MRI lesions in people who stop disease modifying therapy and observational studies such as DISCOMS and DOTMS. He also discussed extended interval dosing with b-cell depleters. www.neurologylive.com/view/discont...
Vitamin D for multiple sclerosis. This network meta-analysis of 32 randomized trials suggests vitamin D is modestly effective and was associated with 20% few relapses and slightly less disability (0.22 points lower on the EDSS scale). www.clinicalnutritionjournal.com/article/S026...
Siponimod (mayzent) in secondary progressive MS reduced EDSS ≥ 7.0 (requiring a wheelchair) by 40% (from the EXPAND randomized trial against placebo) (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.88; p = 0.009) onlinelibrary.wiley.com/doi/10.1111/...
Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system,
with limited effective adjuvant therapies beyond immunomodulatory agents. Vitamin
D supplementation has been pro...
Siponimod lowered the risk of wheelchair use in SPMS patients compared to placebo, especially in those with active disease. Time to wheelchair is a key metric for evaluating treatment in SPMS.
The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis...
